Brand-name and generic pharmaceutical groups are recommending clarifications to the US Food and Drug Administration’s (FDA) guidance on when to submit an abbreviated new drug application (ANDA) or a 505(b)(2) new drug application (NDA), though the groups had different stances on what changes are necessary.